Technical Analysis for STX - Shield Therapeutics Plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.48 | 0.00% | 0.00 |
Earnings due: Apr 25
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Extremely Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hammer Candlestick | Bullish | 0.00% | |
| Lizard Bullish | Bullish Day Trade Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | 1 day ago |
| Outside Day | 1 day ago |
| Up 1% | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
| Down 3% | 1 day ago |
Free Daily (Stock) Chart Reading
Shield Therapeutics Plc Description
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Health Iron Pharmaceutical Medicine Pharmaceuticals Disease Pipe Clinic Hospital Pharmaceutical Industry Clinical Trial Blood Phosphate Clinical Research Inflammatory Bowel Disease Design Of Experiments Kidney Disease Chronic Kidney Disease Hypophosphatemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.85 |
| 52 Week Low | 1.42 |
| Average Volume | 7,111,057 |
| 200-Day Moving Average | 6.59 |
| 50-Day Moving Average | 2.77 |
| 20-Day Moving Average | 1.76 |
| 10-Day Moving Average | 1.55 |
| Average True Range | 0.13 |
| RSI (14) | 13.79 |
| ADX | 75.72 |
| +DI | 3.46 |
| -DI | 38.54 |
| Chandelier Exit (Long, 3 ATRs) | 1.81 |
| Chandelier Exit (Short, 3 ATRs) | 1.81 |
| Upper Bollinger Bands | 2.24 |
| Lower Bollinger Band | 1.28 |
| Percent B (%b) | 0.2 |
| BandWidth | 54.65 |
| MACD Line | -0.36 |
| MACD Signal Line | -0.41 |
| MACD Histogram | 0.0537 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.57 | ||||
| Resistance 3 (R3) | 1.56 | 1.52 | 1.55 | ||
| Resistance 2 (R2) | 1.52 | 1.50 | 1.52 | 1.54 | |
| Resistance 1 (R1) | 1.50 | 1.48 | 1.51 | 1.51 | 1.54 |
| Pivot Point | 1.46 | 1.46 | 1.46 | 1.46 | 1.46 |
| Support 1 (S1) | 1.44 | 1.44 | 1.45 | 1.45 | 1.41 |
| Support 2 (S2) | 1.40 | 1.42 | 1.40 | 1.41 | |
| Support 3 (S3) | 1.38 | 1.40 | 1.40 | ||
| Support 4 (S4) | 1.39 |
